Abstract
The formation of protein aggregates and inclusions in the brain and spinal cord is a common neuropathological feature of a number of neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and many others. These are commonly referred as neurodegenerative proteinopathies or protein-misfolding diseases. The main characteristic of protein aggregates in these disorders is the fact that they are enriched in amyloid fibrils. Since protein aggregation is considered to play a central role for the onset of neurodegenerative proteinopathies, research is ongoing to develop strategies aimed at preventing or removing protein aggregation in the brain of affected patients. Numerous studies have shown that small molecule-based approaches may be potentially the most promising for halting protein aggregation in neurodegenerative diseases. Indeed, several of these compounds have been found to interact with intrinsically disordered proteins and promote their clearing in experimental models. This notwithstanding, at present small molecule inhibitors still awaits achievements for clinical translation. Hopefully, if we determine whether the formation of insoluble inclusions is effectively neurotoxic and find a valid biomarker to assess their protein aggregation-inhibitory activity in the human central nervous system, the use of small molecule inhibitors will be considered as a cure for neurodegenerative protein-misfolding diseases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25(1):239–252
Abraha A, Ghoshal N, Gamblin TC, Cryns V, Berry RW, Kuret J, Binder LI (2000) C-terminal inhibition of tau assembly in vitro and in Alzheimer’s disease. J Cell Sci 113(Pt 21):3737–3745
Akoury E, Pickhardt M, Gajda M, Biernat J, Mandelkow E, Zweckstetter M (2013) Mechanistic basis of phenothiazine-driven inhibition of tau aggregation. Angew Chem Int Ed Engl 52(12):3511–3515. https://doi.org/10.1002/anie.201208290
Amaral L, Kristiansen JE (2001) Phenothiazines: potential management of Creutzfeldt-Jacob disease and its variants. Int J Antimicrob Agents 18(5):411–417
Antonyuk SV, Trevitt CR, Strange RW, Jackson GS, Sangar D, Batchelor M, Cooper S, Fraser C, Jones S, Georgiou T, Khalili-Shirazi A, Clarke AR, Hasnain SS, Collinge J (2009) Crystal structure of human prion protein bound to a therapeutic antibody. Proc Natl Acad Sci U S A 106(8):2554–2558. https://doi.org/10.1073/pnas.0809170106
Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351(3):602–611. https://doi.org/10.1016/j.bbrc.2006.10.093
Attar A, Ripoli C, Riccardi E, Maiti P, Li Puma DD, Liu T, Hayes J, Jones MR, Lichti-Kaiser K, Yang F, Gale GD, Tseng CH, Tan M, Xie CW, Straudinger JL, Klarner FG, Schrader T, Frautschy SA, Grassi C, Bitan G (2012) Protection of primary neurons and mouse brain from Alzheimer’s pathology by molecular tweezers. Brain 135(Pt 12):3735–3748. https://doi.org/10.1093/brain/aws289
Bellucci A, Zaltieri M, Navarria L, Grigoletto J, Missale C, Spano P (2012) From alpha-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson’s disease. Brain Res 1476:183–202. https://doi.org/10.1016/j.brainres.2012.04.014
Benito-Leon J (2004) Combined quinacrine and chlorpromazine therapy in fatal familial insomnia. Clin Neuropharmacol 27(4):201–203
Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K, Knight J, Dickson D, Andorfer C, Rosenberry TL, Lewis J, Hutton M, Janus C (2007) Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 27(14):3650–3662. https://doi.org/10.1523/JNEUROSCI.0587-07.2007
Berriman J, Serpell LC, Oberg KA, Fink AL, Goedert M, Crowther RA (2003) Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc Natl Acad Sci U S A 100(15):9034–9038. https://doi.org/10.1073/pnas.1530287100
Berry RW, Abraha A, Lagalwar S, LaPointe N, Gamblin TC, Cryns VL, Binder LI (2003) Inhibition of tau polymerization by its carboxy-terminal caspase cleavage fragment. Biochemistry 42(27):8325–8331. https://doi.org/10.1021/bi027348m
Bertram L, Tanzi RE (2005) The genetic epidemiology of neurodegenerative disease. J Clin Invest 115(6):1449–1457. https://doi.org/10.1172/JCI24761
Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, Wanker EE (2010) EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci U S A 107(17):7710–7715. https://doi.org/10.1073/pnas.0910723107
Bodea LG, Eckert A, Ittner LM, Piguet O, Gotz J (2016) Tau physiology and pathomechanisms in frontotemporal lobar degeneration. J Neurochem 138(Suppl 1):71–94. https://doi.org/10.1111/jnc.13600
Bodles AM, El-Agnaf OM, Greer B, Guthrie DJ, Irvine GB (2004) Inhibition of fibril formation and toxicity of a fragment of alpha-synuclein by an N-methylated peptide analogue. Neurosci Lett 359(1-2):89–93. https://doi.org/10.1016/j.neulet.2003.12.077
Borchelt DR, Scott M, Taraboulos A, Stahl N, Prusiner SB (1990) Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells. J Cell Biol 110(3):743–752
Bourdenx M, Koulakiotis NS, Sanoudou D, Bezard E, Dehay B, Tsarbopoulos A (2017) Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: examples of amyloidopathies, tauopathies and synucleinopathies. Prog Neurobiol 155:171–193. https://doi.org/10.1016/j.pneurobio.2015.07.003
Boyd JD, Lee P, Feiler MS, Zauur N, Liu M, Concannon J, Ebata A, Wolozin B, Glicksman MA (2014) A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity. J Biomol Screen 19(1):44–56. https://doi.org/10.1177/1087057113501553
Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM (1993) Abnormal tau phosphorylation at Ser396 in Alzheimer’s disease recapitulates development and contributes to reduced microtubule binding. Neuron 10(6):1089–1099
Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, Reaume AG, Scott RW, Cleveland DW (1998) Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281(5384):1851–1854
Bueler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, Weissmann C (1993) Mice devoid of PrP are resistant to scrapie. Cell 73(7):1339–1347
Bulic B, Pickhardt M, Mandelkow EM, Mandelkow E (2010) Tau protein and tau aggregation inhibitors. Neuropharmacology 59(4–5):276–289. https://doi.org/10.1016/j.neuropharm.2010.01.016
Buratti E (2015) Functional significance of TDP-43 mutations in disease. Adv Genet 91:1–53. https://doi.org/10.1016/bs.adgen.2015.07.001
Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, Lu B, Nussbaum RL (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22(20):8797–8807
Casamenti F, Stefani M (2017) Olive polyphenols: new promising agents to combat aging-associated neurodegeneration. Expert Rev Neurother 17(4):345–358. https://doi.org/10.1080/14737175.2017.1245617
Caspi S, Halimi M, Yanai A, Sasson SB, Taraboulos A, Gabizon R (1998) The anti-prion activity of Congo red. Putative mechanism. J Biol Chem 273(6):3484–3489
Caughey B, Raymond GJ (1993) Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J Virol 67(2):643–650
Chang E, Honson NS, Bandyopadhyay B, Funk KE, Jensen JR, Kim S, Naphade S, Kuret J (2009) Modulation and detection of tau aggregation with small-molecule ligands. Curr Alzheimer Res 6(5):409–414
Chang CK, Chiang MH, Toh EK, Chang CF, Huang TH (2013) Molecular mechanism of oxidation-induced TDP-43 RRM1 aggregation and loss of function. FEBS Lett 587(6):575–582. https://doi.org/10.1016/j.febslet.2013.01.038
Chattopadhyay M, Durazo A, Sohn SH, Strong CD, Gralla EB, Whitelegge JP, Valentine JS (2008) Initiation and elongation in fibrillation of ALS-linked superoxide dismutase. Proc Natl Acad Sci U S A 105(48):18663–18668. https://doi.org/10.1073/pnas.0807058105
Cisek K, Cooper GL, Huseby CJ, Kuret J (2014) Structure and mechanism of action of tau aggregation inhibitors. Curr Alzheimer Res 11(10):918–927
Clayton DF, George JM (1998) The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 21(6):249–254
Cohen FE, Pan KM, Huang Z, Baldwin M, Fletterick RJ, Prusiner SB (1994) Structural clues to prion replication. Science 264(5158):530–531
Cohen TJ, Lee VM, Trojanowski JQ (2011) TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol Med 17(11):659–667. https://doi.org/10.1016/j.molmed.2011.06.004
Cohen TJ, Hwang AW, Unger T, Trojanowski JQ, Lee VM (2012) Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking. EMBO J 31(5):1241–1252. https://doi.org/10.1038/emboj.2011.471
Colby DW, Prusiner SB (2011) Prions. Cold Spring Harb Perspect Biol 3(1):a006833. https://doi.org/10.1101/cshperspect.a006833
Collinge J, Gorham M, Hudson F, Kennedy A, Keogh G, Pal S, Rossor M, Rudge P, Siddique D, Spyer M, Thomas D, Walker S, Webb T, Wroe S, Darbyshire J (2009) Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol 8(4):334–344. https://doi.org/10.1016/S1474-4422(09)70049-3
Collins SJ, Lewis V, Brazier M, Hill AF, Fletcher A, Masters CL (2002) Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 52(4):503–506. https://doi.org/10.1002/ana.10336
Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294(5545):1346–1349. https://doi.org/10.1126/science.1063522
Cuchillo R, Michel J (2012) Mechanisms of small-molecule binding to intrinsically disordered proteins. Biochem Soc Trans 40(5):1004–1008. https://doi.org/10.1042/BST20120086
Davidson WS, Jonas A, Clayton DF, George JM (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 273(16):9443–9449
de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, Hyman BT (2010) Caspase activation precedes and leads to tangles. Nature 464(7292):1201–1204. https://doi.org/10.1038/nature08890
DeArmond SJ, Sanchez H, Yehiely F, Qiu Y, Ninchak-Casey A, Daggett V, Camerino AP, Cayetano J, Rogers M, Groth D, Torchia M, Tremblay P, Scott MR, Cohen FE, Prusiner SB (1997) Selective neuronal targeting in prion disease. Neuron 19(6):1337–1348
Del Bo R, Ghezzi S, Corti S, Pandolfo M, Ranieri M, Santoro D, Ghione I, Prelle A, Orsetti V, Mancuso M, Soraru G, Briani C, Angelini C, Siciliano G, Bresolin N, Comi GP (2009) TARDBP (TDP-43) sequence analysis in patients with familial and sporadic ALS: identification of two novel mutations. Eur J Neurol 16(6):727–732. https://doi.org/10.1111/j.1468-1331.2009.02574.x
Dev KK, Hofele K, Barbieri S, Buchman VL, van der Putten H (2003a) Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 45(1):14–44
Dev KK, van der Putten H, Sommer B, Rovelli G (2003b) Part I: parkin-associated proteins and Parkinson’s disease. Neuropharmacology 45(1):1–13
Dickson DW, Kouri N, Murray ME, Josephs KA (2011) Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci 45(3):384–389. https://doi.org/10.1007/s12031-011-9589-0
Dlouhy SR, Hsiao K, Farlow MR, Foroud T, Conneally PM, Johnson P, Prusiner SB, Hodes ME, Ghetti B (1992) Linkage of the Indiana kindred of Gerstmann-Straussler-Scheinker disease to the prion protein gene. Nat Genet 1(1):64–67. https://doi.org/10.1038/ng0492-64
Doig AJ, Derreumaux P (2015) Inhibition of protein aggregation and amyloid formation by small molecules. Curr Opin Struct Biol 30:50–56. https://doi.org/10.1016/j.sbi.2014.12.004
Donne DG, Viles JH, Groth D, Mehlhorn I, James TL, Cohen FE, Prusiner SB, Wright PE, Dyson HJ (1997) Structure of the recombinant full-length hamster prion protein PrP(29-231): the N terminus is highly flexible. Proc Natl Acad Sci U S A 94(25):13452–13457
Dyson HJ, Wright PE (2002) Insights into the structure and dynamics of unfolded proteins from nuclear magnetic resonance. Adv Protein Chem 62:311–340
Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker EE (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15(6):558–566. https://doi.org/10.1038/nsmb.1437
Eisele YS, Monteiro C, Fearns C, Encalada SE, Wiseman RL, Powers ET, Kelly JW (2015) Targeting protein aggregation for the treatment of degenerative diseases. Nat Rev Drug Discov 14(11):759–780. https://doi.org/10.1038/nrd4593
El-Agnaf OM, Irvine GB (2002) Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem Soc Trans 30(4):559–565. https://doi.org/10.1042/bst0300559
El-Agnaf OM, Paleologou KE, Greer B, Abogrein AM, King JE, Salem SA, Fullwood NJ, Benson FE, Hewitt R, Ford KJ, Martin FL, Harriott P, Cookson MR, Allsop D (2004) A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson’s disease and related disorders. FASEB J 18(11):1315–1317. https://doi.org/10.1096/fj.03-1346fje
Eliezer D, Kutluay E, Bussell R Jr, Browne G (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol 307(4):1061–1073. https://doi.org/10.1006/jmbi.2001.4538
Enari M, Flechsig E, Weissmann C (2001) Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci U S A 98(16):9295–9299. https://doi.org/10.1073/pnas.151242598
Fan Y, Wang N, Rocchi A, Zhang W, Vassar R, Zhou Y, He C (2017) Identification of natural products with neuronal and metabolic benefits through autophagy induction. Autophagy 13(1):41–56. https://doi.org/10.1080/15548627.2016.1240855
Farrelly PV, Kenna BL, Laohachai KL, Bahadi R, Salmona M, Forloni G, Kourie JI (2003) Quinacrine blocks PrP (106-126)-formed channels. J Neurosci Res 74(6):934–941. https://doi.org/10.1002/jnr.10849
Fonseca-Ornelas L, Eisbach SE, Paulat M, Giller K, Fernandez CO, Outeiro TF, Becker S, Zweckstetter M (2014) Small molecule-mediated stabilization of vesicle-associated helical alpha-synuclein inhibits pathogenic misfolding and aggregation. Nat Commun 5:5857. https://doi.org/10.1038/ncomms6857
Forny-Germano L, Lyra e Silva NM, Batista AF, Brito-Moreira J, Gralle M, Boehnke SE, Coe BC, Lablans A, Marques SA, Martinez AM, Klein WL, Houzel JC, Ferreira ST, Munoz DP, De Felice FG (2014) Alzheimer’s disease-like pathology induced by amyloid-beta oligomers in nonhuman primates. J Neurosci 34(41):13629–13643. https://doi.org/10.1523/JNEUROSCI.1353-14.2014
Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4(2):160–164. https://doi.org/10.1038/ncb748
Furukawa Y, Fu R, Deng HX, Siddique T, O’Halloran TV (2006) Disulfide cross-linked protein represents a significant fraction of ALS-associated Cu, Zn-superoxide dismutase aggregates in spinal cords of model mice. Proc Natl Acad Sci U S A 103(18):7148–7153. https://doi.org/10.1073/pnas.0602048103
Gabizon R, Rosenmann H, Meiner Z, Kahana I, Kahana E, Shugart Y, Ott J, Prusiner SB (1993) Mutation and polymorphism of the prion protein gene in Libyan Jews with Creutzfeldt-Jakob disease (CJD). Am J Hum Genet 53(4):828–835
Gestwicki JE, Crabtree GR, Graef IA (2004) Harnessing chaperones to generate small-molecule inhibitors of amyloid beta aggregation. Science 306(5697):865–869. https://doi.org/10.1126/science.1101262
Ghaemmaghami S, May BC, Renslo AR, Prusiner SB (2010) Discovery of 2-aminothiazoles as potent antiprion compounds. J Virol 84(7):3408–3412. https://doi.org/10.1128/JVI.02145-09
Ghanta J, Shen CL, Kiessling LL, Murphy RM (1996) A strategy for designing inhibitors of beta-amyloid toxicity. J Biol Chem 271(47):29525–29528
Goedert M, Jakes R (1990) Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J 9(13):4225–4230
Goedert M, Spillantini MG (2006) A century of Alzheimer’s disease. Science 314(5800):777–781. https://doi.org/10.1126/science.1132814
Goedert M, Spillantini MG, Cairns NJ, Crowther RA (1992) Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8(1):159–168
Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, Crowther RA (1996) Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383(6600):550–553. https://doi.org/10.1038/383550a0
Gordon DJ, Meredith SC (2003) Probing the role of backbone hydrogen bonding in beta-amyloid fibrils with inhibitor peptides containing ester bonds at alternate positions. Biochemistry 42(2):475–485. https://doi.org/10.1021/bi0259857
Gordon DJ, Sciarretta KL, Meredith SC (2001) Inhibition of beta-amyloid(40) fibrillogenesis and disassembly of beta-amyloid(40) fibrils by short beta-amyloid congeners containing N-methyl amino acids at alternate residues. Biochemistry 40(28):8237–8245
Hafner-Bratkovic I, Gaspersic J, Smid LM, Bresjanac M, Jerala R (2008) Curcumin binds to the alpha-helical intermediate and to the amyloid form of prion protein – a new mechanism for the inhibition of PrP(Sc) accumulation. J Neurochem 104(6):1553–1564. https://doi.org/10.1111/j.1471-4159.2007.05105.x
Hamada Y, Miyamoto N, Kiso Y (2015) Novel beta-amyloid aggregation inhibitors possessing a turn mimic. Bioorg Med Chem Lett 25(7):1572–1576. https://doi.org/10.1016/j.bmcl.2015.02.016
Hardy J (2017) The discovery of Alzheimer-causing mutations in the APP gene and the formulation of the “amyloid cascade hypothesis”. FEBS J 284(7):1040–1044. https://doi.org/10.1111/febs.14004
Hattori M, Sugino E, Minoura K, In Y, Sumida M, Taniguchi T, Tomoo K, Ishida T (2008) Different inhibitory response of cyanidin and methylene blue for filament formation of tau microtubule-binding domain. Biochem Biophys Res Commun 374(1):158–163. https://doi.org/10.1016/j.bbrc.2008.07.001
Hawkes CA, McLaurin J (2009) Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc Natl Acad Sci U S A 106(4):1261–1266. https://doi.org/10.1073/pnas.0805453106
Hennig J, Andresen C, Museth AK, Lundstrom P, Tibell LA, Jonsson BH (2015) Local destabilization of the metal-binding region in human copper-zinc superoxide dismutase by remote mutations is a possible determinant for progression of ALS. Biochemistry 54(2):323–333. https://doi.org/10.1021/bi500606j
Hernandez DG, Reed X, Singleton AB (2016) Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. J Neurochem 139(Suppl 1):59–74. https://doi.org/10.1111/jnc.13593
Hosokawa-Muto J, Kimura T, Kuwata K (2012) Respiratory and cardiovascular toxicity studies of a novel antiprion compound, GN8, in rats and dogs. Drug Chem Toxicol 35(3):264–271. https://doi.org/10.3109/01480545.2011.598533
Hough MA, Grossmann JG, Antonyuk SV, Strange RW, Doucette PA, Rodriguez JA, Whitson LJ, Hart PJ, Hayward LJ, Valentine JS, Hasnain SS (2004) Dimer destabilization in superoxide dismutase may result in disease-causing properties: structures of motor neuron disease mutants. Proc Natl Acad Sci U S A 101(16):5976–5981. https://doi.org/10.1073/pnas.0305143101
Hsiao K, Baker HF, Crow TJ, Poulter M, Owen F, Terwilliger JD, Westaway D, Ott J, Prusiner SB (1989) Linkage of a prion protein missense variant to Gerstmann-Straussler syndrome. Nature 338(6213):342–345. https://doi.org/10.1038/338342a0
Hughes E, Burke RM, Doig AJ (2000) Inhibition of toxicity in the beta-amyloid peptide fragment beta -(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation. J Biol Chem 275(33):25109–25115. https://doi.org/10.1074/jbc.M003554200
Igaz LM, Kwong LK, Xu Y, Truax AC, Uryu K, Neumann M, Clark CM, Elman LB, Miller BL, Grossman M, McCluskey LF, Trojanowski JQ, Lee VM (2008) Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol 173(1):182–194. https://doi.org/10.2353/ajpath.2008.080003
James TL, Liu H, Ulyanov NB, Farr-Jones S, Zhang H, Donne DG, Kaneko K, Groth D, Mehlhorn I, Prusiner SB, Cohen FE (1997) Solution structure of a 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform. Proc Natl Acad Sci U S A 94(19):10086–10091
Jang BG, In S, Choi B, Kim MJ (2014) Beta-amyloid oligomers induce early loss of presynaptic proteins in primary neurons by caspase-dependent and proteasome-dependent mechanisms. Neuroreport 25(16):1281–1288. https://doi.org/10.1097/WNR.0000000000000260
Johnson BS, McCaffery JM, Lindquist S, Gitler AD (2008) A yeast TDP-43 proteinopathy model: exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci U S A 105(17):6439–6444. https://doi.org/10.1073/pnas.0802082105
Kapurniotu A, Schmauder A, Tenidis K (2002) Structure-based design and study of non-amyloidogenic, double N-methylated IAPP amyloid core sequences as inhibitors of IAPP amyloid formation and cytotoxicity. J Mol Biol 315(3):339–350. https://doi.org/10.1006/jmbi.2001.5244
Karch CM, Prudencio M, Winkler DD, Hart PJ, Borchelt DR (2009) Role of mutant SOD1 disulfide oxidation and aggregation in the pathogenesis of familial ALS. Proc Natl Acad Sci U S A 106(19):7774–7779. https://doi.org/10.1073/pnas.0902505106
Kawasaki Y, Kawagoe K, Chen CJ, Teruya K, Sakasegawa Y, Doh-ura K (2007) Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner. J Virol 81(23):12889–12898. https://doi.org/10.1128/JVI.01563-07
Kayatekin C, Zitzewitz JA, Matthews CR (2010) Disulfide-reduced ALS variants of Cu, Zn superoxide dismutase exhibit increased populations of unfolded species. J Mol Biol 398(2):320–331. https://doi.org/10.1016/j.jmb.2010.02.034
Kim J, Lee H, Lee JH, Kwon DY, Genovesio A, Fenistein D, Ogier A, Brondani V, Grailhe R (2014) Dimerization, oligomerization, and aggregation of human amyotrophic lateral sclerosis copper/zinc superoxide dismutase 1 protein mutant forms in live cells. J Biol Chem 289(21):15094–15103. https://doi.org/10.1074/jbc.M113.542613
Kirby L, Birkett CR, Rudyk H, Gilbert IH, Hope J (2003) In vitro cell-free conversion of bacterial recombinant PrP to PrPres as a model for conversion. J Gen Virol 84(Pt 4):1013–1020. https://doi.org/10.1099/vir.0.18903-0
Kocisko DA, Baron GS, Rubenstein R, Chen J, Kuizon S, Caughey B (2003) New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J Virol 77(19):10288–10294
Kokkoni N, Stott K, Amijee H, Mason JM, Doig AJ (2006) N-methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure. Biochemistry 45(32):9906–9918. https://doi.org/10.1021/bi060837s
Kokubo H, Kayed R, Glabe CG, Staufenbiel M, Saido TC, Iwata N, Yamaguchi H (2009) Amyloid beta annular protofibrils in cell processes and synapses accumulate with aging and Alzheimer-associated genetic modification. Int J Alzheimers Dis 2009:689285. https://doi.org/10.4061/2009/689285
Korth C, May BC, Cohen FE, Prusiner SB (2001) Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A 98(17):9836–9841. https://doi.org/10.1073/pnas.161274798
Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet 18(2):106–108. https://doi.org/10.1038/ng0298-106
Kuwata K, Nishida N, Matsumoto T, Kamatari YO, Hosokawa-Muto J, Kodama K, Nakamura HK, Kimura K, Kawasaki M, Takakura Y, Shirabe S, Takata J, Kataoka Y, Katamine S (2007) Hot spots in prion protein for pathogenic conversion. Proc Natl Acad Sci U S A 104(29):11921–11926. https://doi.org/10.1073/pnas.0702671104
Lanoiselee HM, Nicolas G, Wallon D, Rovelet-Lecrux A, Lacour M, Rousseau S, Richard AC, Pasquier F, Rollin-Sillaire A, Martinaud O, Quillard-Muraine M, de la Sayette V, Boutoleau-Bretonniere C, Etcharry-Bouyx F, Chauvire V, Sarazin M, le Ber I, Epelbaum S, Jonveaux T, Rouaud O, Ceccaldi M, Felician O, Godefroy O, Formaglio M, Croisile B, Auriacombe S, Chamard L, Vincent JL, Sauvee M, Marelli-Tosi C, Gabelle A, Ozsancak C, Pariente J, Paquet C, Hannequin D, Campion D, collaborators of the CNR-MAJ project (2017) APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases. PLoS Med 14(3):e1002270. https://doi.org/10.1371/journal.pmed.1002270
Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P, Quazi AZ, Savalle M, Nemani V, Chaudhry FA, Edwards RH, Stefanis L, Sulzer D (2006) Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 26(46):11915–11922. https://doi.org/10.1523/JNEUROSCI.3821-06.2006
Lassek M, Weingarten J, Einsfelder U, Brendel P, Muller U, Volknandt W (2013) Amyloid precursor proteins are constituents of the presynaptic active zone. J Neurochem 127(1):48–56. https://doi.org/10.1111/jnc.12358
Lendel C, Bertoncini CW, Cremades N, Waudby CA, Vendruscolo M, Dobson CM, Schenk D, Christodoulou J, Toth G (2009) On the mechanism of nonspecific inhibitors of protein aggregation: dissecting the interactions of alpha-synuclein with Congo red and lacmoid. Biochemistry 48(35):8322–8334. https://doi.org/10.1021/bi901285x
Li J, Zhu M, Rajamani S, Uversky VN, Fink AL (2004) Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem Biol 11(11):1513–1521. https://doi.org/10.1016/j.chembiol.2004.08.025
Li J, Browning S, Mahal SP, Oelschlegel AM, Weissmann C (2010) Darwinian evolution of prions in cell culture. Science 327(5967):869–872. https://doi.org/10.1126/science.1183218
Lin WL, Dickson DW (2008) Ultrastructural localization of TDP-43 in filamentous neuronal inclusions in various neurodegenerative diseases. Acta Neuropathol 116(2):205–213. https://doi.org/10.1007/s00401-008-0408-9
Longhena F, Faustini G, Missale C, Pizzi M, Spano P, Bellucci A (2017) The contribution of alpha-Synuclein spreading to Parkinson’s disease Synaptopathy. Neural Plast 2017:5012129. https://doi.org/10.1155/2017/5012129
Lowe TL, Strzelec A, Kiessling LL, Murphy RM (2001) Structure-function relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF. Biochemistry 40(26):7882–7889
Macedo B, Kaschula CH, Hunter R, Chaves JA, van der Merwe JD, Silva JL, Egan TJ, Cordeiro Y (2010) Synthesis and anti-prion activity evaluation of aminoquinoline analogues. Eur J Med Chem 45(11):5468–5473. https://doi.org/10.1016/j.ejmech.2010.07.054
Maeda S, Sahara N, Saito Y, Murayama M, Yoshiike Y, Kim H, Miyasaka T, Murayama S, Ikai A, Takashima A (2007) Granular tau oligomers as intermediates of tau filaments. Biochemistry 46(12):3856–3861. https://doi.org/10.1021/bi061359o
Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, Collinge J (2003) Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302(5646):871–874. https://doi.org/10.1126/science.1090187
Maroteaux L, Campanelli JT, Scheller RH (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8(8):2804–2815
Martinez-Lage JF, Rabano A, Bermejo J, Martinez Perez M, Guerrero MC, Contreras MA, Lunar A (2005) Creutzfeldt-Jakob disease acquired via a dural graft: failure of therapy with quinacrine and chlorpromazine. Surg Neurol 64(6):542–545, discussion 545. https://doi.org/10.1016/j.surneu.2005.03.035
McCord JM, Fridovich I (1969) Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 244(22):6049–6055
Metallo SJ (2010) Intrinsically disordered proteins are potential drug targets. Curr Opin Chem Biol 14(4):481–488. https://doi.org/10.1016/j.cbpa.2010.06.169
Moree B, Yin G, Lazaro DF, Munari F, Strohaker T, Giller K, Becker S, Outeiro TF, Zweckstetter M, Salafsky J (2015) Small molecules detected by second-harmonic generation modulate the conformation of monomeric alpha-Synuclein and reduce its aggregation in cells. J Biol Chem 290(46):27582–27593. https://doi.org/10.1074/jbc.M114.636027
Nakajima M, Yamada T, Kusuhara T, Furukawa H, Takahashi M, Yamauchi A, Kataoka Y (2004) Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 17(3):158–163. https://doi.org/10.1159/000076350
Narayan P, Ehsani S, Lindquist S (2014) Combating neurodegenerative disease with chemical probes and model systems. Nat Chem Biol 10(11):911–920. https://doi.org/10.1038/nchembio.1663
Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, Edwards RH (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65(1):66–79. https://doi.org/10.1016/j.neuron.2009.12.023
Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314(5796):130–133. https://doi.org/10.1126/science.1134108
Nie Q, XG D, Geng MY (2011) Small molecule inhibitors of amyloid beta peptide aggregation as a potential therapeutic strategy for Alzheimer’s disease. Acta Pharmacol Sin 32(5):545–551. https://doi.org/10.1038/aps.2011.14
Niwa J, Yamada S, Ishigaki S, Sone J, Takahashi M, Katsuno M, Tanaka F, Doyu M, Sobue G (2007) Disulfide bond mediates aggregation, toxicity, and ubiquitylation of familial amyotrophic lateral sclerosis-linked mutant SOD1. J Biol Chem 282(38):28087–28095. https://doi.org/10.1074/jbc.M704465200
Nunziante M, Kehler C, Maas E, Kassack MU, Groschup M, Schatzl HM (2005) Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication. J Cell Sci 118(Pt 21):4959–4973. https://doi.org/10.1242/jcs.02609
O’Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, Herron CE, Collinge J, Walsh DM (2010) Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci 30(43):14411–14419. https://doi.org/10.1523/JNEUROSCI.3537-10.2010
Pallitto MM, Ghanta J, Heinzelman P, Kiessling LL, Murphy RM (1999) Recognition sequence design for peptidyl modulators of beta-amyloid aggregation and toxicity. Biochemistry 38(12):3570–3578. https://doi.org/10.1021/bi982119e
Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE et al (1993) Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S A 90(23):10962–10966
Parakh S, Atkin JD (2016) Protein folding alterations in amyotrophic lateral sclerosis. Brain Res 1648(Pt B):633–649. https://doi.org/10.1016/j.brainres.2016.04.010
Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, Schmitt-Ulms G, Mehlhorn IR, Legname G, Wormald MR, Rudd PM, Dwek RA, Burton DR, Prusiner SB (2001) Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412(6848):739–743. https://doi.org/10.1038/35089090
Perrier V, Wallace AC, Kaneko K, Safar J, Prusiner SB, Cohen FE (2000) Mimicking dominant negative inhibition of prion replication through structure-based drug design. Proc Natl Acad Sci U S A 97(11):6073–6078
Perutz MF, Finch JT, Berriman J, Lesk A (2002) Amyloid fibers are water-filled nanotubes. Proc Natl Acad Sci U S A 99(8):5591–5595. https://doi.org/10.1073/pnas.042681399
Petersen RB, Tabaton M, Berg L, Schrank B, Torack RM, Leal S, Julien J, Vital C, Deleplanque B, Pendlebury WW et al (1992) Analysis of the prion protein gene in thalamic dementia. Neurology 42(10):1859–1863
Pickhardt M, Neumann T, Schwizer D, Callaway K, Vendruscolo M, Schenk D, St George-Hyslop P, Mandelkow EM, Dobson CM, McConlogue L, Mandelkow E, Toth G (2015) Identification of small molecule inhibitors of tau aggregation by targeting monomeric tau as a potential therapeutic approach for tauopathies. Curr Alzheimer Res 12(9):814–828
Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW (1993) Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13(4):1676–1687
Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276(5321):2045–2047
Porat Y, Abramowitz A, Gazit E (2006) Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 67(1):27–37. https://doi.org/10.1111/j.1747-0285.2005.00318.x
Price KA, Varghese M, Sowa A, Yuk F, Brautigam H, Ehrlich ME, Dickstein DL (2014) Altered synaptic structure in the hippocampus in a mouse model of Alzheimer’s disease with soluble amyloid-beta oligomers and no plaque pathology. Mol Neurodegener 9:41. https://doi.org/10.1186/1750-1326-9-41
Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216(4542):136–144
Prusiner SB (2004) Early evidence that a protease-resistant protein is an active component of the infectious prion. Cell 116(2 Suppl):S109. 1 p following S113
Prusiner SB, Scott M, Foster D, Pan KM, Groth D, Mirenda C, Torchia M, Yang SL, Serban D, Carlson GA et al (1990) Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell 63(4):673–686
Prusiner SB, Groth D, Serban A, Koehler R, Foster D, Torchia M, Burton D, Yang SL, DeArmond SJ (1993) Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc Natl Acad Sci U S A 90(22):10608–10612
Ramachandran G, Udgaonkar JB (2013) Difference in fibril core stability between two tau four-repeat domain proteins: a hydrogen-deuterium exchange coupled to mass spectrometry study. Biochemistry 52(49):8787–8789. https://doi.org/10.1021/bi4014352
Reinke AA, Gestwicki JE (2007) Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chem Biol Drug Des 70(3):206–215. https://doi.org/10.1111/j.1747-0285.2007.00557.x
Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Wuthrich K (1996) NMR structure of the mouse prion protein domain PrP(121-231). Nature 382(6587):180–182. https://doi.org/10.1038/382180a0
Riek R, Wider G, Billeter M, Hornemann S, Glockshuber R, Wuthrich K (1998) Prion protein NMR structure and familial human spongiform encephalopathies. Proc Natl Acad Sci U S A 95(20):11667–11672
Roberts BL, Patel K, Brown HH, Borchelt DR (2012) Role of disulfide cross-linking of mutant SOD1 in the formation of inclusion-body-like structures. PLoS One 7(10):e47838. https://doi.org/10.1371/journal.pone.0047838
Rocher AB, Crimins JL, Amatrudo JM, Kinson MS, Todd-Brown MA, Lewis J, Luebke JI (2010) Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs. Exp Neurol 223(2):385–393. https://doi.org/10.1016/j.expneurol.2009.07.029
Rosenberg RN, Lambracht-Washington D, Yu G, Xia W (2016) Genomics of Alzheimer disease: a review. JAMA Neurol 73(7):867–874. https://doi.org/10.1001/jamaneurol.2016.0301
Rutherford NJ, Zhang YJ, Baker M, Gass JM, Finch NA, Xu YF, Stewart H, Kelley BJ, Kuntz K, Crook RJ, Sreedharan J, Vance C, Sorenson E, Lippa C, Bigio EH, Geschwind DH, Knopman DS, Mitsumoto H, Petersen RC, Cashman NR, Hutton M, Shaw CE, Boylan KB, Boeve B, Graff-Radford NR, Wszolek ZK, Caselli RJ, Dickson DW, Mackenzie IR, Petrucelli L, Rademakers R (2008) Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet 4(9):e1000193. https://doi.org/10.1371/journal.pgen.1000193
Saccon RA, Bunton-Stasyshyn RK, Fisher EM, Fratta P (2013) Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain 136(Pt 8):2342–2358. https://doi.org/10.1093/brain/awt097
Safar JG, DeArmond SJ, Kociuba K, Deering C, Didorenko S, Bouzamondo-Bernstein E, Prusiner SB, Tremblay P (2005) Prion clearance in bigenic mice. J Gen Virol 86(Pt 10):2913–2923. https://doi.org/10.1099/vir.0.80947-0
Saunders JC, Young LM, Mahood RA, Jackson MP, Revill CH, Foster RJ, Smith DA, Ashcroft AE, Brockwell DJ, Radford SE (2016) An in vivo platform for identifying inhibitors of protein aggregation. Nat Chem Biol 12(2):94–101. https://doi.org/10.1038/nchembio.1988
Selkoe DJ (1992) Aging brain, aging mind. Sci Am 267(3):134–142
Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA (2000) Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A 97(9):4897–4902
Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, Hayes SF, Caughey B (2005) The most infectious prion protein particles. Nature 437(7056):257–261. https://doi.org/10.1038/nature03989
Simoneau S, Rezaei H, Sales N, Kaiser-Schulz G, Lefebvre-Roque M, Vidal C, Fournier JG, Comte J, Wopfner F, Grosclaude J, Schatzl H, Lasmezas CI (2007) In vitro and in vivo neurotoxicity of prion protein oligomers. PLoS Pathog 3(8):e125. https://doi.org/10.1371/journal.ppat.0030125
Singleton A, Gwinn-Hardy K (2004) Parkinson’s disease and dementia with Lewy bodies: a difference in dose? Lancet 364(9440):1105–1107. https://doi.org/10.1016/S0140-6736(04)17117-1
Sinha S, Lopes DH, Du Z, Pang ES, Shanmugam A, Lomakin A, Talbiersky P, Tennstaedt A, McDaniel K, Bakshi R, Kuo PY, Ehrmann M, Benedek GB, Loo JA, Klarner FG, Schrader T, Wang C, Bitan G (2011) Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins. J Am Chem Soc 133(42):16958–16969. https://doi.org/10.1021/ja206279b
Sosa LJ, Caceres A, Dupraz S, Oksdath M, Quiroga S, Lorenzo A (2017) The physiological role of the amyloid precursor protein (APP) as an adhesion molecule in the developing nervous system. J Neurochem. https://doi.org/10.1111/jnc.14122
Soto C, Kindy MS, Baumann M, Frangione B (1996) Inhibition of Alzheimer’s amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun 226(3):672–680. https://doi.org/10.1006/bbrc.1996.1413
Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B (1998) Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer’s therapy. Nat Med 4(7):822–826
Spillantini MG, Goedert M (2013) Tau pathology and neurodegeneration. Lancet Neurol 12(6):609–622. https://doi.org/10.1016/S1474-4422(13)70090-5
Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 95(11):6469–6473
Spires-Jones TL, Stoothoff WH, de Calignon A, Jones PB, Hyman BT (2009) Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci 32(3):150–159. https://doi.org/10.1016/j.tins.2008.11.007
Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle F, de Belleroche J, Mitchell JD, Leigh PN, Al-Chalabi A, Miller CC, Nicholson G, Shaw CE (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319(5870):1668–1672. https://doi.org/10.1126/science.1154584
Staderini M, Legname G, Bolognesi ML, Menendez JC (2013) Modulation of prion by small molecules: from monovalent to bivalent and multivalent ligands. Curr Top Med Chem 13(19):2491–2503
Stahl N, Borchelt DR, Hsiao K, Prusiner SB (1987) Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 51(2):229–240
Supattapone S, Nguyen HO, Cohen FE, Prusiner SB, Scott MR (1999) Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci U S A 96(25):14529–14534
Supattapone S, Wille H, Uyechi L, Safar J, Tremblay P, Szoka FC, Cohen FE, Prusiner SB, Scott MR (2001) Branched polyamines cure prion-infected neuroblastoma cells. J Virol 75(7):3453–3461. https://doi.org/10.1128/JVI.75.7.3453-3461.2001
Takahashi RH, Nagao T, Gouras GK (2017) Plaque formation and the intraneuronal accumulation of beta-amyloid in Alzheimer’s disease. Pathol Int 67(4):185–193. https://doi.org/10.1111/pin.12520
Tang X, Seyb KI, Huang M, Schuman ER, Shi P, Zhu H, Glicksman MA (2012) A high-throughput screening method for small-molecule inhibitors of the aberrant mutant SOD1 and dynein complex interaction. J Biomol Screen 17(3):314–326. https://doi.org/10.1177/1087057111429595
Taylor JP, Hardy J, Fischbeck KH (2002) Toxic proteins in neurodegenerative disease. Science 296(5575):1991–1995. https://doi.org/10.1126/science.1067122
Thompson MJ, Louth JC, Little SM, Chen B, Coldham I (2011) 2,4-diarylthiazole antiprion compounds as a novel structural class of antimalarial leads. Bioorg Med Chem Lett 21(12):3644–3647. https://doi.org/10.1016/j.bmcl.2011.04.090
Tjernberg LO, Naslund J, Lindqvist F, Johansson J, Karlstrom AR, Thyberg J, Terenius L, Nordstedt C (1996) Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem 271(15):8545–8548
Tjernberg LO, Lilliehook C, Callaway DJ, Naslund J, Hahne S, Thyberg J, Terenius L, Nordstedt C (1997a) Controlling amyloid beta-peptide fibril formation with protease-stable ligands. J Biol Chem 272(19):12601–12605
Tjernberg LO, Naslund J, Thyberg J, Gandy SE, Terenius L, Nordstedt C (1997b) Generation of Alzheimer amyloid beta peptide through nonspecific proteolysis. J Biol Chem 272(3):1870–1875
Tofaris GK, Garcia Reitbock P, Humby T, Lambourne SL, O’Connell M, Ghetti B, Gossage H, Emson PC, Wilkinson LS, Goedert M, Spillantini MG (2006) Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J Neurosci 26(15):3942–3950. https://doi.org/10.1523/JNEUROSCI.4965-05.2006
Tomiyama T, Asano S, Suwa Y, Morita T, Kataoka K, Mori H, Endo N (1994) Rifampicin prevents the aggregation and neurotoxicity of amyloid beta protein in vitro. Biochem Biophys Res Commun 204(1):76–83. https://doi.org/10.1006/bbrc.1994.2428
Tomiyama T, Shoji A, Kataoka K, Suwa Y, Asano S, Kaneko H, Endo N (1996) Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J Biol Chem 271(12):6839–6844
Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y, Saitoh T (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 90(23):11282–11286
Ulrih NP, Barry CH, Fink AL (2008) Impact of Tyr to Ala mutations on alpha-synuclein fibrillation and structural properties. Biochim Biophys Acta 1782(10):581–585. https://doi.org/10.1016/j.bbadis.2008.07.004
Upadhaya AR, Lungrin I, Yamaguchi H, Fandrich M, Thal DR (2012) High-molecular weight Aβ oligomers and protofibrils are the predominant Aβ species in the native soluble protein fraction of the AD brain. J Cell Mol Med 16(2):287–295. https://doi.org/10.1111/j.1582-4934.2011.01306.x
Uversky VN (2003) A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J Biomol Struct Dyn 21(2):211–234. https://doi.org/10.1080/07391102.2003.10506918
Uversky VN (2010) Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D(2) concept. Expert Rev Proteomics 7(4):543–564. https://doi.org/10.1586/epr.10.36
Uversky VN, Li J, Fink AL (2001) Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem 276(14):10737–10744. https://doi.org/10.1074/jbc.M010907200
Uversky VN, Oldfield CJ, Dunker AK (2008) Intrinsically disordered proteins in human diseases: introducing the D2 concept. Annu Rev Biophys 37:215–246. https://doi.org/10.1146/annurev.biophys.37.032807.125924
Valentine JS, Doucette PA, Zittin Potter S (2005) Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu Rev Biochem 74:563–593. https://doi.org/10.1146/annurev.biochem.72.121801.161647
Vamvaca K, Volles MJ, Lansbury PT Jr (2009) The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast. J Mol Biol 389(2):413–424. https://doi.org/10.1016/j.jmb.2009.03.021
Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB, Clay D, Wood EM, Chen-Plotkin AS, Martinez-Lage M, Steinbart E, McCluskey L, Grossman M, Neumann M, Wu IL, Yang WS, Kalb R, Galasko DR, Montine TJ, Trojanowski JQ, Lee VM, Schellenberg GD, Yu CE (2008) TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol 7(5):409–416. https://doi.org/10.1016/S1474-4422(08)70071-1
Vergouw LJM, van Steenoven I, van de Berg WDJ, Teunissen CE, van Swieten JC, Bonifati V, Lemstra AW, de Jong FJ (2017) An update on the genetics of dementia with Lewy bodies. Parkinsonism Relat Disord. https://doi.org/10.1016/j.parkreldis.2017.07.009
Watanabe K, Segawa T, Nakamura K, Kodaka M, Konakahara T, Okuno H (2001) Identification of the molecular interaction site of amyloid beta peptide by using a fluorescence assay. J Pept Res 58(4):342–346
Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT Jr (1996) NACP, a protein implicated in Alzheimer’s disease and learning, is natively unfolded. Biochemistry 35(43):13709–13715. https://doi.org/10.1021/bi961799n
Wilcox KC, Lacor PN, Pitt J, Klein WL (2011) Abeta oligomer-induced synapse degeneration in Alzheimer’s disease. Cell Mol Neurobiol 31(6):939–948. https://doi.org/10.1007/s10571-011-9691-4
Wilson DM, Binder LI (1997) Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer’s disease. Am J Pathol 150(6):2181–2195
Wroe SJ, Pal S, Siddique D, Hyare H, Macfarlane R, Joiner S, Linehan JM, Brandner S, Wadsworth JD, Hewitt P, Collinge J (2006) Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 368(9552):2061–2067. https://doi.org/10.1016/S0140-6736(06)69835-8
Yan LM, Tatarek-Nossol M, Velkova A, Kazantzis A, Kapurniotu A (2006) Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis. Proc Natl Acad Sci U S A 103(7):2046–2051. https://doi.org/10.1073/pnas.0507471103
Young LM, Saunders JC, Mahood RA, Revill CH, Foster RJ, Ashcroft AE, Radford SE (2016) ESI-IMS-MS: a method for rapid analysis of protein aggregation and its inhibition by small molecules. Methods 95:62–69. https://doi.org/10.1016/j.ymeth.2015.05.017
Yu Y, Run X, Liang Z, Li Y, Liu F, Liu Y, Iqbal K, Grundke-Iqbal I, Gong CX (2009) Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases. J Neurochem 108(6):1480–1494. https://doi.org/10.1111/j.1471-4159.2009.05882.x
Zahn R, Liu A, Luhrs T, Riek R, von Schroetter C, Lopez Garcia F, Billeter M, Calzolai L, Wider G, Wuthrich K (2000) NMR solution structure of the human prion protein. Proc Natl Acad Sci U S A 97(1):145–150
Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55(2):164–173. https://doi.org/10.1002/ana.10795
Zelko IN, Mariani TJ, Folz RJ (2002) Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med 33(3):337–349
Zhu M, Li J, Fink AL (2003) The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J Biol Chem 278(41):40186–40197. https://doi.org/10.1074/jbc.M305326200
Zhu M, Rajamani S, Kaylor J, Han S, Zhou F, Fink AL (2004) The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J Biol Chem 279(26):26846–26857. https://doi.org/10.1074/jbc.M403129200
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Longhena, F., Spano, P., Bellucci, A. (2017). Targeting of Disordered Proteins by Small Molecules in Neurodegenerative Diseases. In: Ulloa-Aguirre, A., Tao, YX. (eds) Targeting Trafficking in Drug Development. Handbook of Experimental Pharmacology, vol 245. Springer, Cham. https://doi.org/10.1007/164_2017_60
Download citation
DOI: https://doi.org/10.1007/164_2017_60
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-74163-5
Online ISBN: 978-3-319-74164-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)